Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Sales (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Return on Sales for 9 consecutive years, with 11.49% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 1069.0% to 11.49% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Dec 2025, down 65.0% year-over-year, with the annual reading at 0.01% for FY2025, 64.0% down from the prior year.
  • Return on Sales hit 11.49% in Q4 2025 for Protagonist Therapeutics, up from 8.35% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 11.49% in Q4 2025 to a low of 45.51% in Q2 2022.
  • Historically, Return on Sales has averaged 3.73% across 5 years, with a median of 1.23% in 2023.
  • Biggest five-year swings in Return on Sales: plummeted -10654bps in 2021 and later soared 4429bps in 2023.
  • Year by year, Return on Sales stood at 10.32% in 2021, then plummeted by -103bps to 0.3% in 2022, then surged by 997bps to 2.73% in 2023, then plummeted by -71bps to 0.8% in 2024, then skyrocketed by 1339bps to 11.49% in 2025.
  • Business Quant data shows Return on Sales for PTGX at 11.49% in Q4 2025, 8.35% in Q3 2025, and 6.27% in Q2 2025.